Patent details

Basic Information

Publication number:

91409

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP999593965

Legal Status:

Expired

Application number:

91409

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/07/414/001-017 - Galvus-Vildagliptine

Marketing Authorization Type:

Marketing Authorization Date:

28/09/2007

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

16/01/2008

First Marketing Authorization date:

28/09/2007

Grant date:

17/03/2008

Activation date:

09/12/2019

Publication date:

17/03/2008

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

28/09/2022

SPC Extension Expiration:

28/09/2022

Rejection date:

Withdrawal date:

Owner

From:

16/01/2008

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

16/01/2008

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

Name:

VILLHAUER Edwin, Bernard

Address:

United States (US)

Publication

Bulletin

1

Bulletin Heading:

SPC4

Bulletin edition number:

2019/02

Publication date:

22/02/2019

Description:

Section F : Correction of granted supplementary protection certificates – I9 publication

2

Bulletin Heading:

SPC3

Bulletin edition number:

2020/01

Publication date:

13/01/2020

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

24/11/2021

Last Annual Fee Paid Number:

23

Last Annual Fee Paid Amount:

430 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages
02/01/2019	Publication	1
02/01/2019	Outgoing Correspondence	1
19/07/2016	Incoming Correspondence (Post)	2